Alaunos Therapeutics Stock (NASDAQ:TCRT)
Previous Close
$2.52
52W Range
$2.11 - $33.00
50D Avg
$4.06
200D Avg
$12.09
Market Cap
$3.88M
Avg Vol (3M)
$16.79K
Beta
-0.56
Div Yield
-
TCRT Company Profile
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
TCRT Performance
Peer Comparison
Ticker | Company |
---|---|
CKPT | Checkpoint Therapeutics, Inc. |
CUE | Cue Biopharma, Inc. |
ACHL | Achilles Therapeutics plc |
LRMR | Larimar Therapeutics, Inc. |
STOK | Stoke Therapeutics, Inc. |
ADAP | Adaptimmune Therapeutics plc |
BDTX | Black Diamond Therapeutics, Inc. |
RIGL | Rigel Pharmaceuticals, Inc. |
FENC | Fennec Pharmaceuticals Inc. |
LIAN | LianBio |
MDNA | Medicenna Therapeutics Corp. |
MRSN | Mersana Therapeutics, Inc. |
INKT | MiNK Therapeutics, Inc. |
PIRS | Pieris Pharmaceuticals, Inc. |
VRCA | Verrica Pharmaceuticals Inc. |
FIXX | Q32 Bio Inc. |